Cenicriviroc

Cenicriviroc

• CAS Number: 497223-25-3
• UNSPSC Description: Cenicriviroc (TAK-652) is an orally active, dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity[1].
• Target Antigen: CCR; HIV
• Type: Reference compound
• Related Pathways: Anti-infection;GPCR/G Protein;Immunology/Inflammation
• Applications: COVID-19-anti-virus
• Field of Research: Infection; Endocrinology
• Assay Protocol: https://www.medchemexpress.com/Cenicriviroc.html
• Solubility: DMSO : 50 mg/mL (ultrasonic)|Ethanol : 2 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : < 0.1 mg/mL
• Smiles: O=C(/C1=C/C2=CC(C3=CC=C(OCCOCCCC)C=C3)=CC=C2N(CC(C)C)CCC1)NC4=CC=C([S@](CC5=CN=CN5CCC)=O)C=C4
• Molecular Weight: 696.94
• References & Citations: [1]Lefebvre E, et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016 Jun 27;11(6):e0158156|[2]Kuwata T, et al. Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. Antimicrob Agents Chemother. 2015 Nov 2;60(1):437-5|[3]Visseaux B, et al. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates. PLoS One. 2015 Aug 6;10(8):e0134904|[4]Lalezari J, et al. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr. 2011 Jun 1;57(2):118-25.|[5]Baba M, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother. 2005 Nov;49(11):4584-91.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 3